Customized Diagnostic & Therapeutic Development Solutions for Rare Motor Neuron Diseases

Download

As a leading provider of preclinical research services, Protheragen is dedicated to offering tailored diagnostic and therapeutic development solutions for rare movement and neurological disorders. We integrate biomarker discovery, target identification, disease modeling, and innovative drug development to address the complex medical needs of such conditions.

Focusing on the three major disease areas of rare motor neuron diseases (MND), rare musculoskeletal diseases, and rare neurological diseases, our scientists delve into the potential pathogenesis to develop a variety of innovative therapies to address their treatment challenges. We are good at building physiologically relevant in vitro and in vivo models to facilitate disease mechanism research, drug screening and treatment evaluation.

Therapeutic Development Services

Disease Model Development Services

• Patient-Derived Cell Model
• Neuronal Cell Model
• Glial Cell Model
• Co-Culture Model
• Brain Organoid
• Spinal Cord Organoid

In Vitro Model Development

• Neurovascular Unit (NVU) Model
• Axon Degeneration Model
• Neuroinflammation Model
• Neuromuscular Junction Model
• Synaptic Plasticity Model
• Organoid-on-a-Chip Model

Microfluidic Model Development

• Genetically Engineering Model
• Surgery Model
• Induced Disease Model
• Syngeneic Model
• Xenograft Model
• Humanized Animal Model

Animal Model Development

Case Study-APP/PS1 Double Transgenic Mouse Model Development

The APP/PS1 mouse is a double transgenic mouse model utilized for studying the pathogenesis and therapeutic strategies of Alzheimer's disease (AD). This strain, created through transgenic technology, simultaneously expresses human APP (amyloid precursor protein) and PS1 (presenilin 1) mutations. This model can accelerate the pathological development of amyloid protein, accompanied by phenotypes such as Aβ deposition and memory loss.